AzTrials
AzTrials

HypertensioniMedANCT04413500

iMedA: Improving MEDication Adherence Through Person-Centered Care and Adaptive Interventions

A study testing Reminder, Educational message and Motivational messages in people with Hypertension, run by Halmstad University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to design, implement, and evaluate an adaptive personalized digital intervention, to be delivered through a mobile application, to increase medication adherence and self-care management for persons with hypertension. Read more about this study

Who is it for?
Ages 40 to 70 years
Conditions the study is for
Hypertension
What is being tested?
Reminder, Educational message and Motivational messages
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
No sites listed yet
Study dates
Sep 2020to Feb 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • aged 40-70 years old
  • have hypertension diagnosis (i.e. ICD 10 codes from I10 to I16 in the person's medical history) for 1 year or more and have prescribed medications;
  • not receiving medication with unit-dose packaged (Apodos);
  • no previous stroke or myocardial infarction;
  • no psychological disorder or cognitive impairment;
  • no pregnancy-induced hypertension;
  • no insulin treatment;
  • no kidney disease defined as glomerular filtration rate (GFR) <60 ml/min

Who cannot join

  • have no own smartphone
  • not understanding the Swedish language both spoken and written

Trial locations and contacts

No sites are listed yet.

Kobra Etminani contact

+46729773851

kobra.etminani@hh.se

Slawomir Nowaczyk contact

slawomir.nowaczyk@hh.se

About this study

Official title: iMedA: Improving MEDication Adherence Through Person Centered Care and Adaptive Interventions

The aim of this study is to design, implement, and evaluate an adaptive personalized digital intervention, to be delivered through a mobile application, to increase medication adherence and self-care management for persons with hypertension. This is a collaborative project between Halmstad University and Region Halland in Halland county, Sweden.

The project is divided into three steps: 1)Focus groups 2)pilot study 3)Longitudinal study. The design of the study is influenced by the Intervention Mapping technique, which is used for the design and development of health promotion programs. The investigators first conducted a systematic review in order to detect the determinants, behaviors to change, and implemented digital strategies in the previous studies. The result was drawn in the Matrix of Change Objectives to facilitate the mapping. Then through focus groups, the investigators are going to ascertain the needs of the Swedish context. Through what has been learned with these findings, digital interventions will be designed and developed to be delivered via mobile application. A pilot study is considered then to evaluate the feasibility and usability testing of digital intervention. Finally, a longitudinal study is designed to evaluate the effectiveness of the digital intervention in the longer term. The design is proposed to be an interrupted time series (ITS) approach which is considered to be the strongest quasi-experimental design that can be used to evaluate the effectiveness of an intervention.

Read the detailed description

The design of the digital intervention module is considered to follow the just-in-time adaptive intervention framework (JITAI). JITAI is an intervention design aiming to provide the right type/amount of support, at the right time, by adapting to an individual's circumstances. It has enormous potential for promoting health behavior change, which in this study is supposed to be medication compliance. Based on the JITAI's conceptual model, there are the following components:

  1. Decision points (DP) DP is a time when an intervention decision is made. Considering the nature of JITAIs which are delivered through mobiles, DPs are much more rapidly than is standard interventions. In iMedA, DP is considered to be daily and accompanied by the time of medication intake question, i.e. "Did the participant take the anti-hypertensive medication today?".
  2. Intervention options (IO) IOs are a set of possible interventions that are going to be delivered at DPs. In JITAI, IOs can be various types of support (information, advice, feedback, etc), source of support (mobile, nurse, physician, etc), amounts of support (intensity, dose, etc), type of media/channel (phone call, SMS, etc). From the conducted literature review, the investigators summarised all types of digital interventions to hypertensive patients as:
  • Reminders for medication intake (daily), BP measurement (monthly), PA (biweekly)
  • Informational contents regarding hypertension and all its facts, consequences, treatments, risks, medications and side-effects, lifestyle, and so on (text, videos, etc)
  • Trends on medication intake/PA/BP/etc
  • Motivational messages
  1. Distal outcomes (DO) DO is the ultimate goal that the intervention is trying to achieve. In iMedA, the investigators considered primary and secondary DOs. Primarily the investigators aim at improving medication adherence. Then in the long term, blood pressure control is considered as secondary DOs besides the increased quality of life, assessment of the lifestyle behavior (smoking, alcohol consumption, physical activity, and food intake), and communicative and critical health literacy. In order to measure MA, the investigators consider (1) self-reported medication intake through a mobile app; (2) MUAH-16 which is a medication adherence questionnaire for hypertension; and (3) pickups from pharmacies. The self-reported values are supposed to be collected every day. MUAH-16 is measured pre- and post- intervention. BP is considered to be measured every month. There are automatic devices in every primary care center that people can go and measure their BP free of charge. QoL and HL are measured through EQ5D and HL respectively and pre- and post- intervention. Lifestyle assessments are measured (bi)weekly through self-report values.
  2. Proximal outcomes (PO) POs are the short-term goals of the interventions. They can be mediators and/or intermediate measures of the DOs. Medication intake rate is considered to be the main PO, which is measured daily. Physical activity rate which is measured (bi)weekly is another PO. Since most of the contents are educational and they try to increase the hypertension knowledge of the participants, the investigators will add a PO to measure how much their knowledge has increased. The investigators consider two methods to measure it. First, after showing the content, the investigators will ask "Did the participant know …?". Second, a simple gamification test will be designed to be delivered biweekly. To prevent poor adherence to the interventions, it is recommended to define a few POs related to intervention engagement and fatigue. Therefore, the investigators consider the number of clicked interventions, number of watched videos, like/dislike feedbacks per each intervention as POs related to intervention adherence and retention.
  3. Tailoring variables (TV) TVs are information about the participant that are used to decide when to provide which intervention. In other words, they are used to personalise the interventions and make them adaptive to the individual's circumstances. They can be measured actively or passively or both. Active assessments require an individual's engagement in measuring, for example through self-reports, while passive assessments require minimal/no individual engagement, for example through mobile phone's sensors. POs are often used as TVs. From baseline information, a few TVs can be selected including alcohol consumption, smoking, specific diet (vegetarian, vegan, etc), age, and gender, in order to personalise the interventions. All of the POs are also considered as TVs. From the MUAH-16 questionnaire, the investigators start to know more about individual's beliefs, barriers and behaviour about medication adherence. It has four subscales regarding (1)positive attitude towards healthcare and medication; (2) lack of discipline; (3) aversion towards medication; and (4) active coping with health problems. Each subscale contains four questions. At the beginning of the intervention, MUAH-16 questions are used as TVs. Then during the intervention period, and based on the previously delivered informational contents to the individual, the answers to "Did the participant know …?" questions will be used as TVs.
  4. Decision rules (DR) DRs are the adaptation engine of JITAIs. They are used to determine which IO to deliver to whom and when. They are the links between IOs and TVs.

DRs in iMedA will be probabilistic rules from experts modified by "suggestions" from reinforcement learning.

Conditions
Hypertension
Being tested
Reminder, Educational message, Motivational messages, showing trends
Keywords
hypertension, digital intervention, adaptive intervention
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ReminderBehavioural

    A reminder to take the anti-hypertension medication with adjustable frequency.

  • Educational messageBehavioural

    An educational message to increase the knowledge about various facts around hypertension. The short messages are supposed to be sent based on the patient's needs.

  • Motivational messagesBehavioural

    The motivational short messages to increase the motivational levels.

  • showing trendsBehavioural

    Short messages contain different trends of medication intake rate, BP, physical activity rate, and so on.

Study groups in NCT04413500
Study groupRoleWhat they receive
adaptive interventionExperimentalThe patients will receive various adaptive digital interventions through mobile app.
Receives: Behavioral: Reminder; Behavioral: Educational message; Behavioral: Motivational messages; Behavioral: showing trends

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change from baseline medication adherence score at 6 months

    medication adherence score (MA) measured through the Maastricht Utrecht Adherence in Hypertension (MUAH-16) questionnaire.

    The higher score is correlated to better medication adherence. MUAH-16 has 4 subscales: 2 of them measures positive and the other 2 measures negative aspects of medication adherence. Therefore, we consider a positive score for the 2 positive subscales and negative scores to the negative ones. The result will be the final score showing the medication adherence score of the participant.

    The answers are supposed to be on a 7-point Likert scale (1: completely disagree and 7:completely agree). Therefore, the max score will be 48 and the min score will be -48.

    Based on the previous study, there has been shown a correlation between having a higher score and higher medication adherence.

    Measured: 6 months

Secondary outcomes (3)
  1. change from baseline Blood pressure at 6 months

    Systolic and diastolic Blood Pressure (BP). The lower BP the better outcome.

    Measured: 6 months

  2. change from baseline health literacy score at 6 months

    health literacy (HL) measured through the Communicative and Critical Health Literacy Scale.

    We expect to see an increase in HL through time, therefore the higher HL the better outcome.

    Considering the 5-point Likert scale , the max score will be 25 and the min score will be 5.

    Measured: 6 months

  3. change from baseline Quality of Life at 6 months

    quality of life measured through the EuroQol- 5 Dimension (EQ5D) instrument. The higher score the better outcome.

    The answers to each of the five dimensions is between 1-3 scale. The EQ-VAS scale is between 0-100.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jun 2020
  2. Study startSep 2020 (estimated)
  3. Primary completionFeb 2021 (estimated)
  4. Study completionFeb 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
32 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04413500
Sponsor's protocol ID
2017-04617
Other IDs
2017
Acronym
iMedA
Status last verified
Jun 2020
First submitted
22 May 2020
Last updated
11 Jun 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Nahum-Shani I, Smith SN, Spring BJ, Collins LM, Witkiewitz K, Tewari A, Murphy SA. Just-in-Time Adaptive Interventions (JITAIs) in Mobile Health: Key Components and Design Principles for Ongoing Health Behavior Support. Ann Behav Med. 2018 May 18;52(6):446-462. doi: 10.1007/s12160-016-9830-8.

    PubMed 27663578
  • Cabral AC, Castel-Branco M, Caramona M, Fernandez-Llimos F, Figueiredo IV. Developing an adherence in hypertension questionnaire short version: MUAH-16. J Clin Hypertens (Greenwich). 2018 Jan;20(1):118-124. doi: 10.1111/jch.13137. Epub 2017 Nov 24.

    PubMed 29171719
  • Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002 Aug;27(4):299-309. doi: 10.1046/j.1365-2710.2002.00430.x.

    PubMed 12174032
  • Etminani K, Tao Engstrom A, Goransson C, Sant'Anna A, Nowaczyk S. How Behavior Change Strategies are Used to Design Digital Interventions to Improve Medication Adherence and Blood Pressure Among Patients With Hypertension: Systematic Review. J Med Internet Res. 2020 Apr 9;22(4):e17201. doi: 10.2196/17201.

    PubMed 32271148
  • Etminani K, Goransson C, Galozy A, Norell Pejner M, Nowaczyk S. Improving Medication Adherence Through Adaptive Digital Interventions (iMedA) in Patients With Hypertension: Protocol for an Interrupted Time Series Study. JMIR Res Protoc. 2021 May 12;10(5):e24494. doi: 10.2196/24494.

    PubMed 33978593

Questions about this trial

What is this clinical trial studying?

A study testing Reminder, Educational message and Motivational messages in people with Hypertension, run by Halmstad University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kobra Etminani (+46729773851, kobra.etminani@hh.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change from baseline medication adherence score at 6 months (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04413500, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2020; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in